ADDF ACCESS Expansion: In November ADDF expanded and redesigned the ADDF ACCESS portal to provide scientists in academia and small biotechnology companies with access to a larger virtual network of drug discovery experts and contract research organizations that have experience developing therapies for neurodegenerative diseases. Learn more about how ADDF ACCESS is helping researchers accelerate their work.
Sandler Challenge Grant: ADDF board member Randal Sandler and his wife Liz generously pledged $1 million to ADDF in support of a new initiative to accelerate clinical trials of drugs currently used to treat other diseases that are being repurposed for mild cognitive impairment. As part of their pledge, the Sandlers are challenging others to partner with ADDF to raise an additional $3 million for clinical trials by the end of 2014. We want to extend special thanks to those who have already responded to the challenge: The Charles Evans Foundation and their Co-Trustees Mrs. Bonnie Pfeifer Evans and Mrs. Alice Shure, in addition to Mr. Eli Jacobs, Mr. Ray and Barbara Dalio and McCaffrey Family Fund. Learn more.
ADDF Aging + Prevention Program: ADDF has launched Cognitive Vitality, a new program that will provide a credible independent scientific voice to claims about whether certain medicines, supplements and natural products, such as fish oil and coffee, can prevent or delay cognitive aging and Alzheimer’s.
8th Annual Connoisseur’s Dinner: On May 1st, ADDF’s 8th Annual Connoisseur’s Dinner “To Live is to Think,” will be hosted by CBS This Morning anchor Norah O’Donnell at Sotheby’s in NYC. As part of ADDF’s 10th anniversary, we will be honoring Leonard A. Lauder with the Chairman’s Award for his leadership, dedication, and vision to find a cure for Alzheimer’s in his lifetime. Learn more and reserve your ticket now!
Dr. Paul Edison, of the Imperial College of London, has initiated enrollment for a clinical trial investigating whether the diabetes drug liraglutide reduces inflammation and glucose utilization in the brains of people with early Alzheimer’s. ADDF and the Alzheimer’s Society (UK) provided seed funding, which sparked additional investment by other foundations, the UK government and pharmaceutical companies. ADDF is continuing to partner with Alzheimer’s Society (UK) and recently announced a joint funding call for repurposing projects in Alzheimer’s.
In September, Metabolic Solutions Development Company released promising data from an ADDF-funded early stage clinical trial of its mitochondria-targeted drug for early Alzheimer’s disease and is now moving into later stages of development.
ADDF-Canada and The W. Garfield Weston Foundation have financially collaborated to support a clinical trial investigating the potential for hypertension drugs to slow Alzheimer’s progression. The trial will be led by Dr. Sandra Black and the Toronto Dementia Research Alliance at the University of Toronto. Learn more.
• New York Times Letter to the Editor: Key to Fighting Alzheimer’s Costs: New Drugs
• MSNBC: Why isn’t more being done for Alzheimer’s research?
• TEDMED Great Challenges: ADDF's Diana Shineman Participates in "TEDMED Great Challenges: Unraveling Dementia